TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05619237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoSALV Catalytic
Description: NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
Study: NCT05533840

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam

Intervention type: DIAGNOSTIC_TEST
Intervention: ultra-high-resolution computed tomography exams
Description: Participants in the age groups undergo ultra-high-resolution computed tomography exam
Study: NCT04863742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: sustained released dexamethasone, 0.4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
Study: NCT05893459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Debrief
Description: Post-Stressor Discussion with a Friend
Study: NCT04836455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The FDA's The REal Cost vaping prevention ads - Health harms theme
Description: Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The FDA's The Real Cost vaping prevention ads - Addiction theme
Description: Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neutral vaping ads
Description: Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
Study: NCT04774679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endosonographic fine needle aspiration biopsy
Description: An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
Study: NCT05202093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oclean electric toothbrush A
Description: Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral B manual toothbrush
Description: Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oclean electric toothbrush B
Description: Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
Study: NCT05725382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The NOL monitor (Pain Monitoring Device monitor-PMD200™)
Description: NOL-guided perioperative remifentanil administration
Study: NCT05059548

Intervention type: OTHER
Intervention: Video-Assisted Thoracoscopic Surgery
Description: patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia

Intervention type: OTHER
Intervention: Video-Assisted Thoracoscopic Surgery
Description: patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
Study: NCT05561881

Intervention type: OTHER
Group type: OTHER
Intervention: popliteal artery and the capsule of the posterior knee (IPACK) block
Description: ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
Study: NCT06102642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combining free gingival graft with frenotomy procedure
Description: The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
Study: NCT05265130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiFuMai
Description: YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline 250ml
Description: 0.9% Normal Saline 250ml IV, about 40 drops per min.
Study: NCT06281145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart-rate variability biofeedback intervention
Description: Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
Study: NCT04315610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to mobile phone application
Description: Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
Study: NCT05561881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genicular nerves block
Description: ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
Study: NCT05339893

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: In Motion Rehabilitation Robot
Description: Patients will wear the taVNS device on the left ear for the duration of the subsequent phase of the robotic training. During this phase the patient will engage the robotic device with the affected limb and complete the protocol and the stimulation or sham stimulation will occur with every extensor movement.
Study: NCT04315610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Active comparator group, based on traditional information and follow-up.
Study: NCT04494789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone Acetate
Description: 50mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone Acetate
Description: 100mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone Acetate
Description: 200mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: NO Fludrocortisone
Study: NCT06240299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
Study: NCT06113497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail injection
Description: Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
Study: NCT06414538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Mind Map Technique
Description: Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application.
Study: NCT06382844

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
Description: Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
Study: NCT06414538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Method Group
Description: After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
Study: NCT05122767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis.
Study: NCT06382844

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
Description: Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
Description: Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
Description: Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
Study: NCT05639959

Intervention type: DRUG
Intervention: Mometasone Nasal 50 Mcg/Inh Nasal Spray
Description: Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.

Intervention type: DRUG
Intervention: Mometasone Nasal 50 Mcg/Inh Nasal Spray
Description: Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.

Intervention type: DEVICE
Intervention: Nasal spray
Description: device can work properly for actuation during trials

Intervention type: DEVICE
Intervention: Nasal spray
Description: device can work properly for actuation during trials
Study: NCT05149820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Point of Care Randomisation tool
Description: Two designs of electronic point of care randomisation tool will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Point of Care Randomisation tool
Description: Two designs of electronic point of care randomisation tool will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Point of Care Randomisation tool
Description: Two designs of electronic point of care randomisation tool will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Point of Care Randomisation tool
Description: Two designs of electronic point of care randomisation tool will be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
Study: NCT06164158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedural Videos
Description: A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No procedural videos
Description: No procedural videos
Study: NCT05122767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3HP
Description: 3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
Study: NCT05185076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CureSight
Description: watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
Study: NCT06129318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Led Pharmaceutical Care
Description: Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
Study: NCT05000814

Intervention type: DEVICE
Intervention: DLT
Description: VDLT versus the use of DLT with fiberoptic bronchoscope

Intervention type: DEVICE
Intervention: DLT
Description: VDLT versus the use of DLT with fiberoptic bronchoscope
Study: NCT04664855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: 8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
Study: NCT05264961

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: voice therapy
Description: sessions of voice therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: voice therapy
Description: sessions of voice therapy
Study: NCT05739266

Intervention type: BEHAVIORAL
Intervention: 3 minutes step test
Description: 3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
Study: NCT05354024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NDV-HXP-S 10μg
Description: NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), 1 dose (booster)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 30μg
Description: Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 30μg
Description: Vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), 1 dose (booster)
Study: NCT06234618

Intervention type: OTHER
Intervention: visual deprivation
Description: A group of patients walking with eyes open and walking with visual deprivation.
Study: NCT06480201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion amount is dictated by BMI, sex, and age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion amount is dictated by BMI, sex, and age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion amount is dictated by BMI, sex, and age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion amount is dictated by BMI, sex, and age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion amount is dictated by BMI, sex, and age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion amount is dictated by BMI, sex, and age.
Study: NCT05047042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Cancer Support in Virtual Rehabilitation and Exercise
Description: The study intervention will consist of an individualized 8-week program of online exercise modules, supervised interactive group class and one-to-one consultations with an exercise or rehabilitation specialist and a pain and symptom physician, delivered via secure live Zoom sessions.
Study: NCT06463184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
Study: NCT04565457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research CBCT
Description: Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
Study: NCT06568419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic, work-focused Cognitive Behavioural Therapy
Description: Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
Study: NCT04972851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Determined Learning Model of Instruction (SDLMI)
Description: SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Determined Learning Model of Instruction (SDLMI)
Description: SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan
Study: NCT05622383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: aromatherapy,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music concert
Description: music concert

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy and music concert,
Description: aromatherapy and music concert,
Study: NCT04559893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Collaborative care consists of a team of providers that includes a care coordinator, a primary care provider (PCP) and a behavioral health consultant (BHC), who provide evidence- and measurement-based care to a panel of patients using a clinical registry. In our model, the CC team also includes a behavioral health psychotherapist (BHP) who consults on a regular basis but does not deliver direct care.
Study: NCT06578182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5mg tablets once a day for 3 to 4.5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day for 3 to 4.5 years
Study: NCT06117059

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3 fractions of prostate SBRT
Description: Radical radiotherapy using only 3 fractions of prostate SBRT over 3 consecutive days